학술논문

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)
Document Type
Article
Source
In The Lancet Oncology July 2022 23(7):899-909
Subject
Primary Research
Articles
Language
ISSN
1470-2045